Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Unusually active option classes on open April 15th » 09:40
04/15/21
04/15
09:40
04/15/21
09:40
HPE

HP Enterprise

$15.78 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$36.12 /

+ (+0.00%)

, INO

Inovio

$8.85 /

+ (+0.00%)

, MLCO

Melco Resorts & Entertainment

$19.53 /

+ (+0.00%)

, BX

Blackstone

$78.01 /

+ (+0.00%)

, SPCE

Virgin Galactic

$26.65 /

+ (+0.00%)

, TSM

TSMC

$120.87 /

+ (+0.00%)

, AI

C3.ai

$68.41 /

-0.07 (-0.10%)

, V

Visa

$222.14 /

+ (+0.00%)

, DOCU

DocuSign

$225.45 /

+ (+0.00%)

Unusual total active…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

V Visa
$222.14 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

04/08/21 Morgan Stanley
HP Enterprise price target raised to $17 from $15.50 at Morgan Stanley
03/26/21 JPMorgan
HP Enterprise price target raised to $18 from $17 at JPMorgan
03/10/21
Fly Intel: Top five analyst upgrades
03/10/21 Daiwa
HP Enterprise upgraded to Outperform from Neutral at Daiwa
GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink
03/08/21 JPMorgan
JPMorgan double downgrades AnaptysBio back to Underweight after trial miss
INO Inovio
$8.85 /

+ (+0.00%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 BofA
Inovio initiated with a Neutral at BofA
03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

02/25/21 CLSA
Melco Resorts & Entertainment upgraded to Outperform from Underperform at CLSA
01/07/21 Macquarie
Melco Resorts & Entertainment downgraded to Neutral from Outperform at Macquarie
11/17/20 JPMorgan
Melco Resorts & Entertainment price target raised to $25 from $23 at JPMorgan
11/05/20 Roth Capital
Roth Capital trims price target on 'go-to Macau name' Melco Resorts to $30
BX Blackstone
$78.01 /

+ (+0.00%)

04/12/21 Barclays
Blackstone price target raised to $85 from $75 at Barclays
04/09/21 Deutsche Bank
Blackstone price target raised to $66 from $61 at Deutsche Bank
03/19/21
Fly Intel: Top five analyst downgrades
03/18/21 Oppenheimer
Blackstone downgraded to Perform on valuation at Oppenheimer
SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

04/12/21 Bernstein
Virgin Galactic initiated with a Market Perform at Bernstein
03/16/21 Truist
Truist starts 'uniquely positioned' Virgin Galactic at Buy with $50 price target
03/16/21 Truist
Virgin Galactic initiated with a Buy at Truist
03/03/21 BofA
Virgin Galactic price target raised to $50 from $35 at BofA
TSM TSMC
$120.87 /

+ (+0.00%)

04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Atlantic Equities
TSMC initiated with a Neutral at Atlantic Equities
04/01/21 DA Davidson
Onto Innovation price target raised to $80 from $75 at DA Davidson
03/29/21 Citi
TSMC recent selloff brings 'enhanced buying opportunity,' says Citi
AI C3.ai
$68.41 /

-0.07 (-0.10%)

03/02/21 Canaccord
C3.ai price target lowered to $120 from $140 at Canaccord
01/04/21 KeyBanc
C3.ai initiated with a Sector Weight at KeyBanc
01/04/21 Wedbush
Wedbush bullish on C3.ai, initiates with an Outperform
01/04/21 Canaccord
C3.ai initiated with a Hold at Canaccord
V Visa
$222.14 /

+ (+0.00%)

03/19/21 JPMorgan
Visa has 'navigated heavy regulatory oversight' before, says JPMorgan
03/19/21 Wells Fargo
Visa selloff on WSJ story likely a buying opportunity, says Wells Fargo
03/19/21 Barclays
Visa, MasterCard facing new DOJ scrutiny on debt practices, says Barclays
03/16/21 Morgan Stanley
Visa price target raised to $253 from $233 at Morgan Stanley
DOCU DocuSign
$225.45 /

+ (+0.00%)

04/08/21 BofA
BofA reinstates DocuSign at Buy with $250 price target
04/08/21 BofA
DocuSign reinstated with a Buy at BofA
03/29/21 Daiwa
DocuSign initiated with a Buy at Daiwa
03/25/21 DA Davidson
DocuSign still confident in reaching $5B or more in revenue, says DA Davidson
HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

V Visa
$222.14 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

  • 21
    Jan
  • 09
    Dec
  • 13
    Oct
  • 06
    Aug
  • 03
    Jun
  • 20
    May
GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

V Visa
$222.14 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

V Visa
$222.14 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

V Visa
$222.14 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

Recommendations
Texas Roadhouse price target raised to $97 from $81 at Wells Fargo » 08:30
04/15/21
04/15
08:30
04/15/21
08:30
TXRH

Texas Roadhouse

$96.62 /

+0.73 (+0.76%)

Wells Fargo analyst Jon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TXRH Texas Roadhouse
$96.62 /

+0.73 (+0.76%)

TXRH Texas Roadhouse
$96.62 /

+0.73 (+0.76%)

04/12/21 JPMorgan
Texas Roadhouse price target raised to $99 from $90 at JPMorgan
04/01/21 MKM Partners
Texas Roadhouse price target raised to $88 from $83 at MKM Partners
03/31/21 Evercore ISI
Texas Roadhouse price target raised to $95 from $83 at Evercore ISI
03/22/21 BTIG
Texas Roadhouse price target raised to $109 from $92 at BTIG
TXRH Texas Roadhouse
$96.62 /

+0.73 (+0.76%)

TXRH Texas Roadhouse
$96.62 /

+0.73 (+0.76%)

Recommendations
American Eagle price target raised to $40 from $32 at B. Riley » 08:15
04/15/21
04/15
08:15
04/15/21
08:15
AEO

American Eagle

$32.98 /

+0.44 (+1.35%)

B. Riley analyst Susan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

06:59 Today RBC Capital
American Eagle price target raised to $37 from $33 at RBC Capital
06:57 Today Barclays
American Eagle price target raised to $41 from $33 at Barclays
06:16 Today BMO Capital
American Eagle price target raised to $36 from $26 at BMO Capital
03/09/21 Morgan Stanley
American Eagle price target raised to $25 from $18 at Morgan Stanley
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

Downgrade
Lowe's downgraded to Hold from Buy at Zelman » 07:44
04/15/21
04/15
07:44
04/15/21
07:44
LOW

Lowe's

$201.61 /

+1.89 (+0.95%)

Zelman downgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LOW Lowe's
$201.61 /

+1.89 (+0.95%)

LOW Lowe's
$201.61 /

+1.89 (+0.95%)

04/14/21
Fly Intel: Top five analyst upgrades
04/14/21 Atlantic Equities
Atlantic Equities upgrades Lowe's to Overweight on margin momentum
04/14/21 Atlantic Equities
Lowe's upgraded to Overweight from Neutral at Atlantic Equities
04/12/21 Loop Capital
Lowe's price target raised to $220 from $195 at Loop Capital
LOW Lowe's
$201.61 /

+1.89 (+0.95%)

LOW Lowe's
$201.61 /

+1.89 (+0.95%)

LOW Lowe's
$201.61 /

+1.89 (+0.95%)

LOW Lowe's
$201.61 /

+1.89 (+0.95%)

Periodicals
Activist Elliott builds 'multibillion-pound' stake in GlaxoSmithKline, FT says » 07:26
04/15/21
04/15
07:26
04/15/21
07:26
GSK

GlaxoSmithKline

$36.12 /

+0.075 (+0.21%)

Activist hedge fund…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GSK GlaxoSmithKline
$36.12 /

+0.075 (+0.21%)

GSK GlaxoSmithKline
$36.12 /

+0.075 (+0.21%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink
03/08/21 JPMorgan
JPMorgan double downgrades AnaptysBio back to Underweight after trial miss
GSK GlaxoSmithKline
$36.12 /

+0.075 (+0.21%)

GSK GlaxoSmithKline
$36.12 /

+0.075 (+0.21%)

GSK GlaxoSmithKline
$36.12 /

+0.075 (+0.21%)

Recommendations
American Eagle price target raised to $37 from $33 at RBC Capital » 06:59
04/15/21
04/15
06:59
04/15/21
06:59
AEO

American Eagle

$32.98 /

+0.44 (+1.35%)

RBC Capital analyst Kate…

RBC Capital analyst Kate Fitzsimons raised the firm's price target on American Eagle to $37 from $33 and keeps an Outperform rating on the shares. The company followed some of its peers with a "strong" Q1 pre-announcement as sales grew in mid-teens from last year and stronger operating margins drove operating income to about $120M vs. $49M in Q1 of 2019, the analyst tells investors in a research note. Fitzsimons remains positive on American Eagle given its top line momentum associated with growth vehicle Aerie and "self-help on the margin front" at the AE brand thanks to the management's inventory productivity efforts and occupancy reductions.

ShowHide Related Items >><<
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

06:57 Today Barclays
American Eagle price target raised to $41 from $33 at Barclays
06:16 Today BMO Capital
American Eagle price target raised to $36 from $26 at BMO Capital
03/09/21 Morgan Stanley
American Eagle price target raised to $25 from $18 at Morgan Stanley
03/04/21 B. Riley
American Eagle price target raised to $32 from $30 at B. Riley Securities
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

Recommendations
American Eagle price target raised to $41 from $33 at Barclays » 06:57
04/15/21
04/15
06:57
04/15/21
06:57
AEO

American Eagle

$32.98 /

+0.44 (+1.35%)

Barclays analyst Adrienne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

06:16 Today BMO Capital
American Eagle price target raised to $36 from $26 at BMO Capital
03/09/21 Morgan Stanley
American Eagle price target raised to $25 from $18 at Morgan Stanley
03/04/21 B. Riley
American Eagle price target raised to $32 from $30 at B. Riley Securities
03/04/21 Jefferies
American Eagle price target raised to $32 after 'strong quarter' at Jefferies
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

Recommendations
American Eagle price target raised to $36 from $26 at BMO Capital » 06:16
04/15/21
04/15
06:16
04/15/21
06:16
AEO

American Eagle

$32.98 /

+0.44 (+1.35%)

BMO Capital analyst…

BMO Capital analyst Simeon Siegel raised the firm's price target on American Eagle to $36 from $26 and keeps a Market Perform rating on the shares. The company's Q1 pre-announcement was "strong", reflecting its initiatives along with the "economic stimulus, renewed consumer optimism and pent-up demand," the analyst tells investors in a research note. The "trifecta" of tighter industrywide inventory, stronger consumer demand, and economic stimulus should carry forward for the company into Q2, Siegel adds.

ShowHide Related Items >><<
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

03/09/21 Morgan Stanley
American Eagle price target raised to $25 from $18 at Morgan Stanley
03/04/21 B. Riley
American Eagle price target raised to $32 from $30 at B. Riley Securities
03/04/21 Jefferies
American Eagle price target raised to $32 after 'strong quarter' at Jefferies
03/04/21 UBS
American Eagle price target raised to $37 from $31 at UBS
AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

AEO American Eagle
$32.98 /

+0.44 (+1.35%)

Conference/Events
American College of Medical Genetics & Genomics » 04:55
04/15/21
04/15
04:55
04/15/21
04:55
APLT

Applied Therapeutics

$16.57 /

+0.04 (+0.24%)

, BNGO

Bionano Genomics

$6.42 /

-0.47 (-6.82%)

, CNTG

Centogene

$12.23 /

-0.87 (-6.64%)

, DGX

Quest Diagnostics

$127.31 /

-1.055 (-0.82%)

, FIXX

Homology Medicines

$7.22 /

+0.05 (+0.70%)

, FOLD

Amicus

$9.98 /

+0.67 (+7.20%)

, ILMN

Illumina

$398.29 /

-4.72 (-1.17%)

, NTRA

Natera

$101.43 /

-5.78 (-5.39%)

, NVTA

Invitae

$39.08 /

-0.29 (-0.74%)

, RARE

Ultragenyx

$107.91 /

+1.26 (+1.18%)

, SNY

Sanofi

$50.26 /

+0.16 (+0.32%)

, TAK

Takeda Pharmaceutical

$17.06 /

+0.055 (+0.32%)

, UA

Under Armour

$18.43 /

-0.13 (-0.70%)

, XFOR

X4 Pharmaceuticals

$8.98 /

+0.6 (+7.16%)

Annual Clinical Genetics…

Annual Clinical Genetics Virtual Meeting of ACMG to be held on April 13-16. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$8.98 /

+0.6 (+7.16%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

RARE Ultragenyx
$107.91 /

+1.26 (+1.18%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

NTRA Natera
$101.43 /

-5.78 (-5.39%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

CNTG Centogene
$12.23 /

-0.87 (-6.64%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

11/17/20 Barclays
Applied Therapeutics price target lowered to $44 from $64 at Barclays
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
04/22/20
Fly Intel: Top five analyst initiations
BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
CNTG Centogene
$12.23 /

-0.87 (-6.64%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FOLD Amicus
$9.98 /

+0.67 (+7.20%)

04/14/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
04/13/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
ILMN Illumina
$398.29 /

-4.72 (-1.17%)

04/06/21 Wells Fargo
Illumina price target raised to $330 from $300 at Wells Fargo
04/06/21 Canaccord
Illumina price target raised to $460 from $445 at Canaccord
04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
03/31/21 Canaccord
Canaccord upgrades Illumina, says worth owning with or without Grail
NTRA Natera
$101.43 /

-5.78 (-5.39%)

03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
01/19/21 BTIG
Natera price target raised to $135 from $112 at BTIG
NVTA Invitae
$39.08 /

-0.29 (-0.74%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
RARE Ultragenyx
$107.91 /

+1.26 (+1.18%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
SNY Sanofi
$50.26 /

+0.16 (+0.32%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

04/05/21
Fly Intel: Top five analyst downgrades
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
04/05/21 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
03/03/21 RBC Capital
Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
UA Under Armour
$18.43 /

-0.13 (-0.70%)

02/22/21 Williams Capital
Under Armour initiated with a Hold at Williams Trading
02/19/21 Oppenheimer
Opco upgrades Under Armour on potential return to 'outsized' sales growth
02/19/21 Oppenheimer
Under Armour upgraded to Outperform from Perform at Oppenheimer
02/11/21 Jefferies
Under Armour price target raised to $30 from $25 at Jefferies
XFOR X4 Pharmaceuticals
$8.98 /

+0.6 (+7.16%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
XFOR X4 Pharmaceuticals
$8.98 /

+0.6 (+7.16%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

RARE Ultragenyx
$107.91 /

+1.26 (+1.18%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

NTRA Natera
$101.43 /

-5.78 (-5.39%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

CNTG Centogene
$12.23 /

-0.87 (-6.64%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

  • 07
    Apr
  • 12
    Feb
  • 22
    Jan
  • 20
    Jan
  • 08
    Jan
  • 29
    Oct
  • 11
    Sep
  • 10
    Jul
UA Under Armour
$18.43 /

-0.13 (-0.70%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

NTRA Natera
$101.43 /

-5.78 (-5.39%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

Upgrade
AB InBev upgraded to Overweight from Equal Weight at Barclays » 04:50
04/15/21
04/15
04:50
04/15/21
04:50
BUD

AB InBev

$65.13 /

+0.76 (+1.18%)

Barclays analyst Laurence…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BUD AB InBev
$65.13 /

+0.76 (+1.18%)

BUD AB InBev
$65.13 /

+0.76 (+1.18%)

04/06/21 Deutsche Bank
AB InBev named 'Catalyst Call - Sell Idea' at Deutsche Bank
03/01/21 Morgan Stanley
AB InBev price target lowered to EUR 56 from EUR 61 at Morgan Stanley
02/26/21 Barclays
AB InBev price target raised to EUR 59 from EUR 54 at Barclays
02/26/21 RBC Capital
AB InBev price target lowered to EUR 67 from EUR 71 at RBC Capital
BUD AB InBev
$65.13 /

+0.76 (+1.18%)

BUD AB InBev
$65.13 /

+0.76 (+1.18%)

BUD AB InBev
$65.13 /

+0.76 (+1.18%)

BUD AB InBev
$65.13 /

+0.76 (+1.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.